The antilipolytic effect of peptide YY (PYY) and neuropeptide Y has recently been shown in human adipocytes. PYY receptors were investigated in three human adipose deposits. A greater number of 125I-labeled PYY binding sites was found in femoral adipocyte membranes (maximal binding = 40 +/- 4 fmol/mg protein; dissociation constant = 0.3 +/- 0.1 nM) when compared with mammary and pericolonic adipose tissue. PYY receptors, like alpha 2-adrenergic sites, were largely expressed in femoral fat cells. Such a distribution was not specific either to inhibitory or to stimulating adenylyl cyclase systems since adenosine A1 and beta-adrenergic receptors were more numerous in pericolonic adipocytes. On isolated adipocytes, PYY (10(-7) M) inhibited lipolysis by 58 +/- 2% in femoral and 14 +/- 4% in pericolonic fat cells; epinephrine had the following similar response: 62 +/- 5 and 26 +/- 8%, respectively. A close relationship between the number of alpha 2-sites and PYY sites and the antilipolytic effects initiated by PYY and an alpha 2-agonist was observed. No significant differences were noted in the amount of Gi proteins in femoral and pericolonic adipocyte membranes.
No takes yet. Share an insight, caveat, or question.
Castan‐Laurell et al. (1993) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: